Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Impact of ruxolitinib approval on myelofibrosis real-world survival in the US

Srdan Verstovsek, MD, PhD, of the University of Texas MD Anderson Cancer Center, Houston, TX, outlines the impact of ruxolitinib’s approval in 2011 on real-world data of elderly myelofibrosis patients in the United States. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).